Embodiments of the invention relate to a ventilation device comprising: a. a ventilation tube having proximal and distal ends; and b. an inflatable cuff having a proximal bulge portion and a distal neck portion disposed distal to the bulge portion, the inflatable cuff being mounted around the ventilation tube to define proximal and distal cuff attachment locations which are both fixed on an outer surface of the ventilation tube.

A syringe pump is disclosed that includes a pressure sensor assembly, a plunger, first and second pressure sensors, and a processor. The pressure sensor assembly senses a force and includes the plunger having a sensing surface configured to receive the force, the first pressure sensor operatively coupled to the plunger and configured to estimate the force applied to the sensing surface, and the second pressure sensor operatively coupled to the plunger and configured to estimate the force applied to the sensing surface. The processor is coupled to the first and second pressure sensors to estimate a magnitude of the force.

The present disclosure is directed to a device for screening pre-filled syringes configured to determine whether a stopper position within each syringe falls within an acceptable tolerance prior to final assembly of a syringe into a corresponding autoinjector device, thereby ensuring proper fit of the syringe within the autoinjector device and further ensuring accurate delivery of a desired dose of fluid from the syringe during operation of the autoinjector.

A patient interface for delivery of a supply of pressurised air or breathable gas to an entrance of a patient's airways comprising: a cushion member that includes a retaining structure and a seal-forming structure permanently connected to the retaining structure; a frame member attachable to the retaining structure; and a positioning and stabilising structure attachable to the frame member.

The present invention relates to a novel nasal spray containing an aqueous solution or a fluid with an anxiolytic or anticonvulsant substance, wherein the nasal spray is characterized in that with the nasal spray, two sprays with each an equivalent, defined volume of the aqueous solution or liquid of the active agent, can be intranasally administered to a patient and wherein the nasal spray allows for an administration, independent of the spatial orientation of the nasal spray in any position of the patient (standing upright, sitting, lying or in any intermediate position). The nasal spray can be used directly without prior activation. Preferably it is apparent from the nasal spray whether a spray or even a second spray has been made with the nasal spray. Preferably, a spray of the nasal spray can be administered one-handed by the patient or a third person. The active agent in the inventive nasal spray is a benzodiazepine or a GABA-receptor agonist, preferably midazolam or a derivative thereof or a salt of these active agents. The nasal spray according to the present invention may be used for sedation, premedication or treatment of patients with claustrophobia, anxiety disorders or panic attacks or for the treatment of convulsions in CNS diseases, particularly in epileptic seizures or other manifestations of seizures (e.g. febrile convulsions). The invention also relates to a method for hermetically sealing an active agent container for use in supplying an nasal spray in accordance with the invention. The invention also relates to a method of detection by localizing the locally precise administration of an active agent in nasal application, as well as a nasal spray, preferably a bi-dose nasal spray, for which, using the cited method of detection, it has been shown both visually (qualitatively) and quantitatively that an orientation-independent, uniform and locally precise administration of the dose of the active agent onto the nasal mucosa of a patient can be achieved. Also provided is a method for airless and air-tight sealing of an active agent container in accordance with the invention.

A method for in vitro simulation and evaluation of platelet adhesion in blood-contacting medical devices is disclosed, including the following steps: (1) using a glycerin aqueous solution with a mass percentage concentration of 40% in an extracorporeal circulation circuit to simulate a viscosity and hydrodynamic characteristics of blood, and adding fluorescent particles with a diameter of 3 μm to 5 μm to the solution to simulate platelets; (2) after the solution circulates in the circuit for a specified time period, removing flow passage components of a tested device, and observing the deposition of the fluorescent particles on a blood-contacting surface inside the device by naked eyes and photographs; and (3) using laser-induced fluorescence (LIF) technique to apply laser light on a device surface deposited with the fluorescent particles and in contact with blood, and using charge-coupled device (CCD) camera imaging to photograph the aggregation and adhesion of laser-induced fluorescent particles.

The present invention is an apparatus that gives patency to the respiratory tract to reduce suffocating feeling by maintaining a pressure higher than atmospheric pressure in the nasopharynx during exhalation; an apparatus that is equipped with an air flow part communicating with a nasal mask covering user's nostrils or with user's nostrils and a casing forming a chamber for temporarily holding the exhaled air of the user; and provides a breathing apparatus that is equipped with a first opening provided in the casing for discharging the exhaled air temporarily held in the casing to the outside and an exhalation control valve that releases exhaled air to the first opening side at the start of exhalation of the user and closes the first opening when the pressure in the chamber on the nostril side exceeds a predetermined value due to exhalation.

A device for delivering a predetermined volume a substance within a body cavity. The device includes: at least one predefined volume sized and shaped to contain a predetermined volume the substance; a delivery end in fluid communication with a container; and at least one valve mechanically connected to the container and configurable between an active configuration in which the valve enables delivery of a volume of the substance and an inactive configuration, in which the valve prevents delivery.

A 3D printed biocompatible drug delivery device is provided having a fluid delivery channel distinguishing three segments and a receiving chamber with an array of microneedles. The three segments of the delivery channel are stagnation zones before a drug is extruded and whereby an inverted funnel provides an increasing extrusion surface servicing the drug to the array of microneedles. The design of the device with its flow-related components circumvents the challenge of colloidal stability associated with multi-phase formulations leading to nozzle blockage. Qualitative screening cytotoxicity tests pre and post-extrusion through the drug delivery device using mammalian cells rule out cytotoxicity and outline equivalent viability to control treatments. The biocompatibility results suggest that the fluid delivery design, the photoresin selected as well as the fabrication and sterilization may be extended over a range of regenerative medicine and drug delivery applications.

A syringe pump is disclosed that includes a body, a syringe seat, a syringe actuator, a memory, and one or more processors. The syringe seat is coupled to the body. The syringe actuator is configured to actuate a syringe secured within the syringe seat. The memory is configured to store a plurality of instructions. The one or more processors, in accordance with the plurality of instructions, is/are configured to: prime the syringe pump in a prime phase; determine if an occlusion exists during the prime phase using a first test; stop the prime phase; initiate fluid delivery into a patient; enter into a start-up phase; determine if an occlusion exists using a second test during the start-up phase; transition from the start-up phase into a steady-state phase; and determine if an occlusion exists during the steady-state phase using a third test.